New Strategies for Venue in Hatch-Waxman Litigation

March 13, 2015

Venue can have a dramatic impact on Hatch-Waxman Act litigation. Brands and generics are constantly looking for new strategies to secure a favorable venue. Until recently, the ability of brands to choose and hold venue has resulted in almost all Hatch-Waxman cases going to federal courts in Delaware or New Jersey. In those districts, it can be very difficult for generics to have a summary judgment motion heard and the time to disposition may take at least a full 30 months during which time a stay of Food and Drug Administration approval remains in effect.

The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.


Jake M. Holdreith


Managing Partner, Minneapolis Office
Member of Executive Board

Jamie R. Kurtz


Co-Chair, Health Care Litigation Group

Kelsey Mcelveen

Related Publications

First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
March 25, 2024
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2024
Mallinckrodt plc v. Airgas Therapeutics LLC
GENERICally Speaking Hatch Waxman Bulletin
March 8, 2024
UCB, Inc. v. Mylan Techs. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 5, 2024
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top